Related references
Note: Only part of the references are listed.Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM)
Soren Moller et al.
OSTEOPOROSIS INTERNATIONAL (2022)
One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data
Sara Khalid et al.
OSTEOPOROSIS INTERNATIONAL (2022)
Assessment and management of imminent fracture risk in the setting of the fracture liaison service
M. K. Javaid et al.
OSTEOPOROSIS INTERNATIONAL (2022)
Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study
Alicia Gilsenan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
C-reactive protein and fracture risk: an updated systematic review and meta-analysis of cohort studies through the use of both frequentist and Bayesian approaches
H. Mun et al.
OSTEOPOROSIS INTERNATIONAL (2021)
The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2021)
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
Nannan Li et al.
PHARMACOECONOMICS (2021)
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
E. Soreskog et al.
OSTEOPOROSIS INTERNATIONAL (2021)
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
E. Soreskog et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Athanasios D. Anastasilakis et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension
Sabashini K. Ramchand et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study
E. V. McCloskey et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
Peter Burckhardt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines A report for the National Osteoporosis Guideline Group (NOGG)
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Short time horizons for fracture prediction tools: time for a rethink
E. V. McCloskey et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
Takahiro Mori et al.
ARCHIVES OF OSTEOPOROSIS (2021)
Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data
Peyman Hadji et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2021)
Validation of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data
Michael K. Skjodt et al.
BONE (2021)
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review
Laura P. B. Elbers et al.
DRUGS (2021)
Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models
Sara Khalid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
Takahiro Mori et al.
ARCHIVES OF OSTEOPOROSIS (2021)
SCOPE 2021: a new scorecard for osteoporosis in Europe
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2021)
Management of osteoporosis in older men
Jean-Marc Kaufman
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2021)
Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people
J. Barnsley et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2021)
Role of bone-forming agents in the management of osteoporosis
Michael R. McClung
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2021)
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Eben G. Estell et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Understanding patients' preferences for osteoporosis treatment: the impact of patients' characteristics on subgroups and latent classes
D. Cornelissen et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2020)
History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture
Emese Toth et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Dolores Shoback et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective
Mickael Hiligsmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review
D. Cornelissen et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
N. R. Fuggle et al.
DRUGS (2020)
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis
Andreas Fontalis et al.
BONE (2020)
High Circulating Sphingosine 1-Phosphate is a Risk Factor for Osteoporotic Fracture Independent of Fracture Risk Assessment Tool
Seung Hun Lee et al.
CALCIFIED TISSUE INTERNATIONAL (2020)
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Persistence and adherence to parenteral osteoporosis therapies: a systematic review
G. Koller et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Deep Learning With Electronic Health Records for Short-Term Fracture Risk Identification: Crystal Bone Algorithm Development and Validation
Yasmeen Adar Almog et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2020)
2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)
Ferrari Serge et al.
SWISS MEDICAL WEEKLY (2020)
A decade of FRAX: how has it changed the management of osteoporosis?
John A. Kanis et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2020)
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
Quang A. Le et al.
ANNALS OF PHARMACOTHERAPY (2019)
Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Adolfo Diez-Perez et al.
BONE (2019)
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
F. Fatoye et al.
BMJ OPEN (2019)
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis
Mattias Lorentzon et al.
ADVANCES IN THERAPY (2019)
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
R. Eastell et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture
Mickael Hiligsmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
Takahiro Mori et al.
JBMR PLUS (2019)
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
M. B. Zanchetta et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
Jean-Yves Reginster et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
Albrecht Werner Popp et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries
Katrine Hass Rubin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Characteristics of recurrent fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464)
N. C. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Review of the guideline of the American College of Physicians on the treatment of osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)
Masayo Sato et al.
ARCHIVES OF OSTEOPOROSIS (2018)
A systematic review of factors affecting medication adherence among patients with osteoporosis
C. T. Yeam et al.
OSTEOPOROSIS INTERNATIONAL (2018)
A brief history of FRAX
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2018)
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Imminent risk of fracture after fracture
H. Johansson et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Felicia Cosman et al.
MAYO CLINIC PROCEEDINGS (2017)
The Utility of Biomarkers in Osteoporosis Management
Patrick Garnero
MOLECULAR DIAGNOSIS & THERAPY (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The association between serum uric acid level and the risk of fractures: a systematic review and meta-analysis
P. Yin et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment
Mickael Hiligsmann et al.
RHEUMATOLOGY (2017)
UK clinical guideline for the prevention and treatment of osteoporosis
J. Compston et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Gary Hattersley et al.
ENDOCRINOLOGY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL DENSITOMETRY (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A systematic review of intervention thresholds based on FRAX A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2016)
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Burden of high fracture probability worldwide: secular increases 2010-2040
A. Oden et al.
OSTEOPOROSIS INTERNATIONAL (2015)
FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
N. C. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX
N. C. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2015)
FRAX-based assessment and intervention thresholds-an exploration of thresholds in women aged 50 years and older in the UK
E. McCloskey et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
Yanfei L. Ma et al.
BONE (2014)
A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
Helena Johansson et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment
Mickael Hiligsmann et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Worldwide uptake of FRAX
J. A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2014)
Progressively Increasing Fracture Risk With Advancing Age After Initial Incident Fragility Fracture: The Tromso Study
Luai Awad Ahmed et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Cystatin C and risk of hip fractures in older women
Kristine E. Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
A systematic review of hip fracture incidence and probability of fracture worldwide
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2012)
The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland
Mickael Hiligsmann et al.
VALUE IN HEALTH (2012)
Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1
Davide Gatti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Secular trends in the incidence of hip and other osteoporotic fractures
C. Cooper et al.
OSTEOPOROSIS INTERNATIONAL (2011)
A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence
Susan Ross et al.
VALUE IN HEALTH (2011)
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
P. Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Predicting Risk of Osteoporotic Fracture in Men and Women in England and Wales: Prospective Derivation and Validation of QFractureScores
P. Mikosch
JOURNAL FUR MINERALSTOFFWECHSEL (2010)
Clinical subsequent fractures cluster in time after first fractures
T. A. C. M. van Geel et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial
Kenneth G. Saag et al.
ARTHRITIS AND RHEUMATISM (2009)
Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks
N. D. Nguyen et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Mechanisms of anabolic therapies for osteoporosis
Ernesto Canalis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of fracture on bone turnover markers:: A longitudinal study comparing marker levels before and after injury in 113 elderly women
Kaisa K. Ivaska et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
R Prince et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
JM Kaufman et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
